{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T17:36:06Z","timestamp":1774114566382,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:00:00Z","timestamp":1496188800000},"content-version":"vor","delay-in-days":150,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2017]]},"DOI":"10.6061\/clinics\/2017(05)10","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T12:02:03Z","timestamp":1496404923000},"page":"317-324","source":"Crossref","is-referenced-by-count":41,"title":["Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients"],"prefix":"10.1016","volume":"72","author":[{"given":"Rosa Camila","family":"Lucchetta","sequence":"first","affiliation":[]},{"given":"Bruno Salgado","family":"Riveros","sequence":"additional","affiliation":[]},{"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[]},{"given":"Rosana Bento","family":"Radominski","sequence":"additional","affiliation":[]},{"given":"Michel Fleith","family":"Otuki","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Fernandez-Llimos","sequence":"additional","affiliation":[]},{"given":"Cassyano Janu\u00e1rio","family":"Correr","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.6061\/clinics\/2017(05)10_bib1","author":"WHO \u2013 World Health Organization"},{"issue":"13","key":"10.6061\/clinics\/2017(05)10_bib2","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1001\/archinte.161.13.1581","article-title":"Impact of overweight on the risk of developing common chronic diseases during a 10-year period","volume":"161","author":"Field","year":"2001","journal-title":"Arch Intern Med"},{"issue":"Suppl 8A","key":"10.6061\/clinics\/2017(05)10_bib3","doi-asserted-by":"crossref","first-page":"37S","DOI":"10.1016\/j.amjmed.2003.08.012","article-title":"Obesity as a cardiovascular risk factor","volume":"115","author":"Sowers","year":"2003","journal-title":"Am J Med"},{"key":"10.6061\/clinics\/2017(05)10_bib4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1186\/1471-2458-12-440","article-title":"The costs of overweight and obesity-related diseases in the Brazilian public health system: cross-sectional study","volume":"12","author":"Bahia","year":"2012","journal-title":"BMC Public Health"},{"issue":"25 Suppl 2","key":"10.6061\/clinics\/2017(05)10_bib5","first-page":"S102","article-title":"2013 AHA\/ACC\/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"10.6061\/clinics\/2017(05)10_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4239\/wjd.v2.i2.19","article-title":"Rise and fall of anti-obesity drugs","volume":"2","author":"Li","year":"2011","journal-title":"World J Diabetes"},{"issue":"8","key":"10.6061\/clinics\/2017(05)10_bib7","first-page":"1763","article-title":"[Prescription, dispensing, and regulation of psychoactive anorexigenic drugs in Belo Horizonte, Minas Gerais, Brazil]","volume":"24","author":"Carneiro Mde","year":"2008","journal-title":"Cad Saude Publica"},{"issue":"2","key":"10.6061\/clinics\/2017(05)10_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1471-0153(01)00054-X","article-title":"Use of anorectic amphetamine-like drugs by Brazilian women","volume":"3","author":"Nappo","year":"2002","journal-title":"Eat Behav"},{"issue":"3","key":"10.6061\/clinics\/2017(05)10_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/(SICI)1099-1557(199805\/06)7:3<207::AID-PDS335>3.0.CO;2-W","article-title":"Inappropriate prescribing of compounded antiobesity formulas in Brazil","volume":"7","author":"Nappo","year":"1998","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"10.6061\/clinics\/2017(05)10_bib10","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3109\/10826089809058951","article-title":"Use of amphetamine-like appetite suppressants: a cross-sectional survey in Southern Brazil","volume":"33","author":"de Lima","year":"1998","journal-title":"Subst Use Misuse"},{"key":"10.6061\/clinics\/2017(05)10_bib11","author":"C\u00e2mara dos Deputados (Brasil)"},{"issue":"3","key":"10.6061\/clinics\/2017(05)10_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.38","article-title":"Discrepancies in listed adverse drug reactions in pharmaceutical product information supplied by the regulatory authorities in Denmark and the USA","volume":"2","author":"Eriksson","year":"2014","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"10.6061\/clinics\/2017(05)10_bib13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/annonc\/mdt512","article-title":"How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers\u2019 views","volume":"25","author":"Tafuri","year":"2014","journal-title":"Ann Oncol"},{"issue":"9","key":"10.6061\/clinics\/2017(05)10_bib14","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archinte.164.9.994","article-title":"The efficacy and safety of sibutramine for weight loss: a systematic review","volume":"164","author":"Arterburn","year":"2004","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.6061\/clinics\/2017(05)10_bib15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1467-789X.2009.00567.x","article-title":"Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis","volume":"10","author":"Fabricatore","year":"2009","journal-title":"Obes Rev"},{"issue":"3","key":"10.6061\/clinics\/2017(05)10_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/dom.12198","article-title":"The effect of antiobesity drugs on waist circumference: A mixed treatment comparison","volume":"16","author":"Chilton","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.6061\/clinics\/2017(05)10_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"11","key":"10.6061\/clinics\/2017(05)10_bib18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.6061\/clinics\/2017(05)10_bib19","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"issue":"6","key":"10.6061\/clinics\/2017(05)10_bib20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/000992286700600607","article-title":"Treatment of obesity in underprivileged adolescents. Comparison of diethylpropion hydrochloride with placebo in a double-blind study","volume":"6","author":"Andelman","year":"1967","journal-title":"Clin Pediatr"},{"issue":"3","key":"10.6061\/clinics\/2017(05)10_bib21","first-page":"271","article-title":"A double-blind trial of mazindol using a very low calorie formula diet","volume":"1","author":"Baird","year":"1977","journal-title":"Int J Obes"},{"issue":"6","key":"10.6061\/clinics\/2017(05)10_bib22","first-page":"816","article-title":"Double-blind clinical evaluation of mazindol (42-548) in obese diabetics","volume":"18","author":"Bandisode","year":"1975","journal-title":"Curr Ther Res Clin Exp"},{"issue":"3","key":"10.6061\/clinics\/2017(05)10_bib23","first-page":"209","article-title":"A double-blind evaluation of Tenuate dospan in overweight patients from a private gynecologic practice","volume":"38","author":"Bolding","year":"1968","journal-title":"J Med Assoc State Ala"},{"issue":"1","key":"10.6061\/clinics\/2017(05)10_bib24","first-page":"40","article-title":"Diethylpropion hydrochloride: an effective appetite suppressant","volume":"16","author":"Bolding","year":"1974","journal-title":"Curr Ther Res Clin Exp"},{"issue":"5","key":"10.6061\/clinics\/2017(05)10_bib25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/030006057400200505","article-title":"Mazindol in obesity with known cardiac disease","volume":"2","author":"Bradley","year":"1974","journal-title":"J Int Med Res"},{"issue":"137","key":"10.6061\/clinics\/2017(05)10_bib26","first-page":"463","article-title":"[Clinical trial with a nonamphetaminic anoretic]","volume":"23","author":"Campagnoli","year":"1976","journal-title":"Rev Iber Endocrinol"},{"issue":"1","key":"10.6061\/clinics\/2017(05)10_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5694\/j.1326-5377.1975.tb118095.x","article-title":"Double blind evaluation of long acting diethylpropion hydrochloride in obese patients from a general practice","volume":"1","author":"Carney","year":"1975","journal-title":"Med J Aust"},{"issue":"8","key":"10.6061\/clinics\/2017(05)10_bib28","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ijo.2009.124","article-title":"A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects","volume":"33","author":"Cercato","year":"2009","journal-title":"Int J Obes"},{"issue":"7","key":"10.6061\/clinics\/2017(05)10_bib29","first-page":"358","article-title":"Double-blind clinical evaluation of mazindol, dextroamphetamine, and placebo in treatment of exogenous obesity","volume":"15","author":"Defelice","year":"1973","journal-title":"Curr Ther Res Clin Exp"},{"issue":"622","key":"10.6061\/clinics\/2017(05)10_bib30","first-page":"321","article-title":"A double-blind controlled study of the use of diethylpropion hydrochloride (Tenuate) in obese patients in a rural practice","volume":"88","author":"Elliott","year":"1978","journal-title":"N Z Med J"},{"issue":"11","key":"10.6061\/clinics\/2017(05)10_bib31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/j.1552-4604.1972.tb00246.x","article-title":"Mazindol, a new non-amphetamine anorexigenic agent","volume":"12","author":"Hadler","year":"1972","journal-title":"J Clin Pharmacol New Drugs"},{"issue":"14","key":"10.6061\/clinics\/2017(05)10_bib32","doi-asserted-by":"crossref","first-page":"566","DOI":"10.5694\/j.1326-5377.1975.tb106063.x","article-title":"Double-blind trial of mazindol in overweight patients","volume":"2","author":"Heber","year":"1975","journal-title":"Med J Aust"},{"issue":"1305","key":"10.6061\/clinics\/2017(05)10_bib33","first-page":"431","article-title":"A multi-centre general practice trial of mazindol in the treatment of obesity","volume":"218","author":"Maclay","year":"1977","journal-title":"Practitioner"},{"issue":"5","key":"10.6061\/clinics\/2017(05)10_bib34","first-page":"437","article-title":"Clinical assessment of the use of an anorectic drug in a total weight reduction program","volume":"17","author":"McQuarrie","year":"1975","journal-title":"Curr Ther Res Clin Exp"},{"issue":"2","key":"10.6061\/clinics\/2017(05)10_bib35","first-page":"332","article-title":"Use of an anorexic drug in a total weight reduction program in private practice","volume":"18","author":"Nolan","year":"1975","journal-title":"Curr Ther Res Clin Exp"},{"issue":"5","key":"10.6061\/clinics\/2017(05)10_bib36","first-page":"329","article-title":"Controlled-release diethylpropion hydrochloride used in a program for weight reduction","volume":"3","author":"Parsons","year":"1981","journal-title":"Clin Ther"},{"key":"10.6061\/clinics\/2017(05)10_bib37","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1742-1241.1964.tb00682.x","article-title":"The use of diethylpropion in the treatment of obesity","volume":"18","author":"DERAMOS","year":"1964","journal-title":"Br J Clin Pract"},{"issue":"5231","key":"10.6061\/clinics\/2017(05)10_bib38","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/bmj.1.5231.1009","article-title":"Diethyl-propion in the treatment of &ldquo;refractory&rdquo; obesity","volume":"1","author":"SEATON","year":"1961","journal-title":"Br Med J"},{"issue":"3","key":"10.6061\/clinics\/2017(05)10_bib39","first-page":"193","article-title":"Double blind clinical trial of mazindol on weight loss blood glucose, plasma insulin and serum lipids in overweight diabetic patients","volume":"4","author":"Slama","year":"1978","journal-title":"Diabete Metab"},{"issue":"5978","key":"10.6061\/clinics\/2017(05)10_bib40","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bmj.3.5978.284","article-title":"Double-blind evaluation of mazindol in refractory obesity","volume":"3","author":"Smith","year":"1975","journal-title":"Br Med J"},{"issue":"8","key":"10.6061\/clinics\/2017(05)10_bib41","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/ijo.2013.225","article-title":"A comparative study of five centrally acting drugs on the pharmacological treatment of obesity","volume":"38","author":"Suplicy","year":"2014","journal-title":"Int J Obes"},{"issue":"2","key":"10.6061\/clinics\/2017(05)10_bib42","first-page":"149","article-title":"A controlled trial of mazindol (Sanjorex, Teronac) in the management of the obese rheumatic patients","volume":"17","author":"Thorpe","year":"1975","journal-title":"Curr Ther Res Clin Exp"},{"issue":"11","key":"10.6061\/clinics\/2017(05)10_bib43","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5694\/j.1326-5377.1976.tb140662.x","article-title":"AN 448 Sandoz (Mazindol) in the treatment of obesity","volume":"1","author":"Wallace","year":"1976","journal-title":"Med J Aust"},{"issue":"197","key":"10.6061\/clinics\/2017(05)10_bib44","first-page":"411","article-title":"Trial of a long-acting preparation of diethylpropion in obese diabetics","volume":"200","author":"Williams","year":"1968","journal-title":"Practitioner"},{"issue":"5","key":"10.6061\/clinics\/2017(05)10_bib45","first-page":"351","article-title":"Transient ischemic attacks associated with amfepramone therapy: a case report","volume":"8","author":"Crols","year":"1993","journal-title":"Funct Neurol"},{"issue":"7996","key":"10.6061\/clinics\/2017(05)10_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(76)91728-1","article-title":"Schizophrenia-like reaction to diethylpropion","volume":"2","author":"Fookes","year":"1976","journal-title":"Lancet"},{"issue":"4","key":"10.6061\/clinics\/2017(05)10_bib47","first-page":"351","article-title":"Diet pill psychosis","volume":"116","author":"Hoffman","year":"1977","journal-title":"Can Med Assoc J"},{"issue":"5306","key":"10.6061\/clinics\/2017(05)10_bib48","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/bmj.2.5306.729-d","article-title":"Diethylpropion","volume":"2","author":"Kuenssberg","year":"1962","journal-title":"Br Med J"},{"issue":"2","key":"10.6061\/clinics\/2017(05)10_bib49","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1556-4029.2006.00078.x","article-title":"Abusive prescription of psychostimulants: a study of two cases","volume":"51","author":"Pelissier-Alicot","year":"2006","journal-title":"J Forensic Sci"},{"key":"10.6061\/clinics\/2017(05)10_bib50","first-page":"86","article-title":"A clinical evaluation of tenuate\u2013a new anti-appetite compound","volume":"46","author":"Wilson","year":"1960","journal-title":"J Ir Med Assoc"},{"key":"10.6061\/clinics\/2017(05)10_bib51","author":"U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER)"},{"key":"10.6061\/clinics\/2017(05)10_bib52","unstructured":"Brasil, Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa). Nota t\u00e9cnica sobre efic\u00e1cia e seguran\u00e7a dos medicamentos inibidores de apetite, 2011."},{"issue":"5","key":"10.6061\/clinics\/2017(05)10_bib53","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7453\/gahmj.2013.008","article-title":"The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development","volume":"2","author":"Gagnier","year":"2013","journal-title":"Glob Adv Health Med"},{"issue":"7","key":"10.6061\/clinics\/2017(05)10_bib54","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","article-title":"Meta-analysis: pharmacologic treatment of obesity","volume":"142","author":"Li","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.6061\/clinics\/2017(05)10_bib55","first-page":"6","author":"Roberts","year":"2009","journal-title":"Standard Evaluation Framework for weight management interventions [Internet]"},{"key":"10.6061\/clinics\/2017(05)10_bib56","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1471-2288-11-160","article-title":"Characteristics of meta-analyses and their component studies in the Cochrane Database of Systematic Reviews: a cross-sectional, descriptive analysis","volume":"11","author":"Davey","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"10.6061\/clinics\/2017(05)10_bib57","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12874-015-0024-z","article-title":"The heterogeneity statistic I(2) can be biased in small meta-analyses","volume":"15","author":"von Hippel","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"10.6061\/clinics\/2017(05)10_bib58","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.290.7.921","article-title":"Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events","volume":"290","author":"Als-Nielsen","year":"2003","journal-title":"JAMA"}],"updated-by":[{"DOI":"10.6061\/clinics\/2018\/e1err","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000}}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222007955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222007955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T21:52:53Z","timestamp":1692827573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222007955"},"secondary":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1807-59322017000500317&lng=en&nrm=iso&tlng=en","label":"SCIELO"},{"URL":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5439101\/?report=classic","label":"PMC"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"alternative-id":["S1807593222007955"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2017(05)10","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}